# OnCo record eltrombopag (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/eltrombopag/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "eltrombopag" ;
  schema:name "Eltrombopag"@en ;
  schema:alternateName "Eltrombopag Olamine"@en, "SB-497115"@en, "Promacta / Revolade" ;
  schema:description "Eltrombopag is a daily tablet that raises platelet counts by stimulating the bone marrow; it is approved for immune thrombocytopenia and severe aplastic anaemia, and haematologists also use it when low platelets complicate blood cancers and their treatment."@en ;
  schema:url <https://onco.cc/drugs/eltrombopag/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Eltrombopag> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=eltrombopag>, <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022291> ;
  onco:status "established" ;
  onco:tag "gap-fill", "supportive-care" ;
  onco:modality "Oral thrombopoietin receptor agonist" ;
  onco:approval "US 2008: Chronic immune thrombocytopenia with insufficient response to corticosteroids, immunoglobulins or splenectomy" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/mds/> ;
  onco:technologies <https://onco.cc/fronts/supportive-care/> ;
  onco:targets <https://onco.cc/targets/mpl/> ;
  onco:drugs <https://onco.cc/drugs/romiplostim/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:terms <https://onco.cc/terms/thrombocytopenia/> ;
  onco:trials <https://onco.cc/trials/nct03603795/>, <https://onco.cc/trials/nct01890746/>, <https://onco.cc/trials/nct01772420/> .